Relay Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
The following table describes, for the three month period ended December 31, 2025, each trading arrangement for the sale or purchase of our securities adopted, materially modified, orterminated by our directors and officers that is a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, or a Rule 10b5-1 trading arrangement. No other officers or directors adopted, materially modified, or terminated a Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement during the three month period ended December 31, 2025.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Expiration Date | Aggregate Number of Securities |
|---|---|---|---|---|
| Donald A. Bergstrom (President, Research and Development) | Adoption (10/30/2025) | Rule 10b5-1 Trading Arrangement | The earlier of (i) 11/20/2026 and (ii) the completed sale of the maximum shares subject to the plan. | Up to 120,915 Shares |
| Peter Rahmer(Chief Corporate Development Officer) | Adoption (10/31/2025) | Rule 10b5-1 Trading Arrangement | The earlier of (i) 10/15/2026 and (ii) the completed sale of the maximum shares subject to the plan. | Up to 100,000 Shares |
| Thomas Catinazzo (Chief Financial Officer) | Adoption (10/30/2025) | Rule 10b5-1 Trading Arrangement | The earlier of (i) 12/17/2026 and (ii) the completed sale of the maximum shares subject to the plan. | Up to 388,418 Shares |
| Sanjiv K. Patel (President and Chief Executive Officer) | Adoption(10/30/2025) | Rule 10b5-1 Trading Arrangement | The earlier of (i) 11/23/2026 and (ii) the completed sale of the maximum shares subject to the plan. | Up to 240,998 Shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.